The rationale is to use the phenolic compound to remodel the immunosuppressive tumor microenvironment—for example, by inhibiting CD73 and reducing adenosine—thus sensitizing the tumor to a more potent attack by the co-administered ICI. Here, NT5E is linked to neoplasm.